Granted Patent B2

US 12,435,141 · App. 16/745,064 · Granted Oct 7, 2025

Inventors: David T. Ho (Long Beach, CA); Tove Olafsen (Reseda, CA); Giti Agahi (Los Angeles, CA); Christian P. Behrenbruch (Inglewood, CA)

Assignee: IMAGINAB, INC.

C07K16/2815A61K47/6849A61K51/1027G01N33/566G01N33/6872A61K2039/505C07K2317/24C07K2317/31C07K2317/35C07K2317/56C07K2317/565C07K2317/622C07K2317/624C07K2317/626C07K2317/92G01N2333/70517

Abstract

Claims (49)

1. A method of detecting a presence or absence of a CD8, the method comprising:

applying a humanized antigen binding construct to a sample, the antigen binding construct comprising:

a HCDR1 of SEQ ID NO: 3 or 6;

a HCDR2 of SEQ ID NO: 3 or 6;

a HCDR3 of SEQ ID NO: 3 or 6;

a LCDR1 of SEQ ID NO: 9;

a LCDR2 of SEQ ID NO: 9;

a LCDR3 of SEQ ID NO: 9; and

a LFR1 of a LFR1 of SEQ ID NO: 42; and

detecting a presence or an absence of the antigen binding construct, thereby detecting a presence or absence of a CD8.

2. The method of claim 1 , wherein the antigen binding construct is conjugated to a detectable marker.

3. The method of claim 1 , wherein applying the antigen binding construct comprises administering the antigen binding construct to a subject.

4. The method of claim 1 , wherein detecting binding or absence of binding of the antigen binding construct to CD8 comprises at least one of positron emission tomography or single-photon emission computed tomography.

5. The method of claim 1 , further comprising applying a secondary antigen binding construct to the sample, wherein the secondary antigen binding construct binds specifically to the antigen binding construct.

6. The method of claim 1 , wherein the antigen binding construct is incubated with the sample for no more than 20 hours.

7. The method of claim 1 , wherein the antigen binding construct is incubated with the sample for no more than 6 hours.

8. The method of claim 1 , wherein the antigen binding construct is administered to a host, and wherein a first quantity of antigen binding construct thereof is unbound to CD8, and a second quantity of antigen binding construct is bound to CD8, wherein at least about 80% of the first quantity of antigen binding construct is eliminated in no more than 12 hours.

9. The method of claim 1 , wherein the antigen binding construct comprises a minibody comprising a polypeptide that comprises, from N-terminus to C-terminus:

a single-chain variable fragment (scFv) that binds to CD8, the scFv comprising a variable heavy (V H ) domain linked to a variable light (V L ) domain,

the V H domain comprising the HCDR1, the HCDR2, and the HCDR3, and

the V L domain comprising the LCDR1, the LCDR2, and the LCDR3.

10. The method of claim 1 , wherein the antigen binding construct comprises a cys-diabody comprising:

a single-chain variable fragment (scFv) comprising a variable heavy (V H ) domain linked to a variable light (V L ) domain; and

a C-terminal cysteine.

11. The method of claim 1 , the antigen binding construct comprising a HFR3 of a HFR3 of SEQ ID NO: 48.

12. The method of claim 1 , wherein the antigen binding construct comprises:

a V H domain that is a V H domain of SEQ ID NO: 48, the V H domain comprising the HCDR1, the HCDR2, and the HCDR3; and

a V L domain that is a V L domain of SEQ ID NO: 42, the V L domain comprising the LCDR1, the LCDR2, and the LCDR3.

13. The method of claim 2 , wherein the antigen binding construct comprises:

a V H domain comprising the amino acid sequence of SEQ ID NO: 48, the V H domain comprising the HCDR1, the HCDR2, and the HCDR3; and

a V L domain comprising the amino acid sequence of SEQ ID NO: 42, the V L domain comprising the LCDR1, the LCDR2, and the LCDR3.

14. The method of claim 2 , wherein the detectable marker is selected from the group consisting of 18 F, 18 F-FAC, 32 P, 33 P, 45 Ti, 47 Sc, 52 Fe, 59 Fe, 62 Cu, 64 Cu, 67 Cu, 67 Ga, 68 Ga, 75 Sc, 77 As, 86 Y, 90 Y, 89 Sr, 89 Zr, 94 Tc, 94 Tc, 99 mTc, 99 Mo, 105 Pd, 105 Rh, 111 Ag, 111 In, 123 I, 124 I, 125 I, 131 I, 142 Pr, 143 Pr, 149 Pm, 153 Sm, 154-158 Gd, 161 Tb, 166 Dy, 166 Ho, 169 Er, 175 Lu, 177 Lu, 186 Re, 188 Re, 189 Re, 194 Ir, 198 Au, 199 Au, 211 At, 211 Pb, 212 Bi, 212 Pb, 213 Bi, 223 Ra and 225 Ac.

15. The method of claim 2 , wherein the detectable marker comprises 89 Zr.

16. A method of detecting a presence or absence of a CD8, the method comprising:

applying an antigen binding construct to a sample, the antigen binding construct comprising:

a HCDR1 of SEQ ID NO: 3 or 6;

a HCDR2 of SEQ ID NO: 3 or 6;

a HCDR3 of SEQ ID NO: 3 or 6;

a LCDR1 of SEQ ID NO: 9;

a LCDR2 of SEQ ID NO: 9;

a LCDR3 of SEQ ID NO: 9; and

(i) a HFR3 of a HFR3 of SEQ ID NO: 48, and/or (ii) a LFR1 of a LFR1 of SEQ ID NO: 42; and

detecting a presence or an absence of the antigen binding construct, thereby detecting a presence or absence of a CD8.

17. The method of claim 16 , wherein the antigen binding construct comprises a minibody comprising:

a V H domain comprising the amino acid sequence of SEQ ID NO: 48, the V H domain comprising the HCDR1, the HCDR2, and the HCDR3; and

a V L domain comprising the amino acid sequence of SEQ ID NO: 42, the V L domain comprising the LCDR1, the LCDR2, and the LCDR3.

18. The method of claim 17 , wherein applying the antigen binding construct comprises administering the antigen binding construct to a subject.

19. The method of claim 18 , wherein the antigen binding construct is conjugated to a detectable marker.

20. The method of claim 19 , wherein the detectable marker comprises 89 Zr.

Assignments (2)

Continuity (5)

References Cited (400)